Introduction
In 2007 a hierarchical scheme for classification of lymphoid neoplasms for epidemiology was proposed by members of the International Lymphoma Epidemiology Consortium (InterLymph) to further the aims of etiologic research. 1 The InterLymph scheme defined standardized groupings of lymphoid neoplasms at a range of hierarchical levels, and provided a method for utilizing cases coded under previous classification schemes (Working Formulation, in pooled studies. In epidemiologic studies, this hierarchical classification has facilitated subtype-specific analyses to the most detailed extent possible based on the sample size and level of pathology information available, which is critical for comparing subtype-specific data among studies, achieving homogeneity among cases diagnosed using different systems within a single study, and for combining data from multiple studies for pooled analyses. The InterLymph classification scheme has been adopted by individual epidemiologic studies, 4 pooled analyses, 5-10 descriptive epidemiologic studies using cancer registry data, 11 and by the 2009 Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review.
12
were proposed for new entities without ICD-O-3 codes; these were expected to be incorporated in the 4th edition of ICD-O but remained subject to changes. (proposed ICD-O-4) codes. We therefore believe it is important to include these entities in the updated classification, so that their epidemiology may be studied, and to enable cancer registries to recognize where they should be placed in classification of lymphoid neoplasms.
As with the previous classification, we recommend methodologies for incorporating the 2008 WHO classification in future studies and for converting cases classified using previous classification schemes, which is essential for long term studies such as cohort studies, completed or ongoing studies, and calculation of time trends. with Epstein-Barr virus infection). These characteristics may be shared across different subtypes, which precludes nesting them in the classification structure.
All of the major WHO 2008 entities and provisional entities are included in the updated classification, except for some proposed divisions within subtypes that would be impracticable to incorporate into epidemiologic studies, such as the morphologic variants of mantle cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. Readers are referred to the 2008 WHO publication 13 for criteria for the different lymphoid neoplasm subtypes. Very rare subtypes are accounted for so they can be analyzed in large studies with sufficient case numbers or pooled studies. Provisional WHO borderline categories between diffuse large BFor personal use only. on October 24, 2017. by guest www.bloodjournal.org From cell lymphoma (DLBCL), usually primary mediastinal type, and classical Hodgkin lymphoma, and between DLBCL and Burkitt lymphoma are included. Categories are also provided for lymphomas of B-cell, T-cell and unknown lineage that are not otherwise specified (NOS).
Lymphomas of more than one histological type found in one patient at any site and approximately the same time are listed as "multiple coexisting lymphoma subtypes". Tables 1 and 2 lesions have not been placed in hierarchical groups, but this can be done in studies which identify significant numbers of these cases.
Results
In the previous nested classification scheme, we did not address the immunodeficiencyassociated lymphoproliferative disorders defined in the 2001 and 2008 WHO classifications because of their complex relationship with other lymphoid neoplasms, the coding difficulties mentioned above, and the exclusion of these cases from most population-based epidemiologic studies. It is acknowledged that reporting of these conditions will be incomplete and, in the iatrogenic immunodeficiency group, there are difficulties in distinguishing an immunosuppressive therapy effect from an underlying disease effect. 25 However, populationbased epidemiologic studies have shown that these conditions have distinct lymphoma profiles, 26 and they have provided important insights into lymphomagenesis because of their association with oncogenic viral infections. 27 We recommend that these conditions be noted hematopoietic neoplasms in an individual. In etiologic studies, the low-grade NHL should be used in analyses when two codes are identified as recommended in the previous InterLymph classification paper. 1 However, in survival studies, we suggest that the high-grade lymphoma is likely more relevant because it determines both the natural history and treatment approach. Table 3 .
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The authors declare no competing financial interests. k Cases of ENNKTL ocurring outside the upper aerodigestive tract ("extranasal" ENNKTL) share the same ICD-O-3 code but show different behavior, so may be considered separately in analyses.
e ICD-O-3 codes for MALT lymphoma and nodal marginal zone lymphoma are the same (9699/3), so if site is not specified, these entities may be grouped as non-splenic MZL for analyses.
j Rare cases of acute lymphoblastic leukemia/lymphoma with an NK-cell phenotype are described.
f The WHO 2008 classification does not provide any specific definitions of age.
i Cases of LYG with progression to EBV positive DLBCL with no inflammatory background should be classified as DLBCL, with a note that they are LYG-associated (DLBCL-LYG). c The distinction between LPL and other lymphomas, especially MZL, is not always clear-cut, and some cases may need to be diagnosed as a small B-cell lymphoma with plasmacytic differentiation and a differential diagnosis provided. d Heavy chain diseases share a single ICD-0-3 code 9762, but usually gamma heavy chain disease is associated with lymphoplasmacytic lymphoma, mu heavy chain disease with a variety of NHLs, and alpha heavy chain disease with MALT lymphoma. Such cases should be grouped with specific histological types where possible.
b Currently recognised recurrent genetic abnormalities are listed in the WHO 2008 publication.
h Most cases of DLBCL may be divided into germinal center (GC) and non-germinal center (non-GC) B cell subtypes. Various methods for ascertaining the type may be used (see Discussion).
g Pediatric nodal marginal zone lymphoma can be analyzed as a separate group from other nodal marginal zone lymphoma.
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